

Cyclacel Pharmaceuticals, Inc.
 Form 4
 February 14, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
MORGAN STANLEY

2. Issuer Name and Ticker or Trading Symbol
**Cyclacel Pharmaceuticals, Inc.
 [CYCC]**

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
1585 BROADWAY
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
01/03/2007

____ Director 10% Owner
 ____ Officer (give title below) ____ Other (specify below)

NEW YORK, NY 10036
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/03/2007		P		44,200	A	\$ 6.86	1,797,344	I	By Subsidiary (1)
Common Stock	01/03/2007		S		44,200	D	\$ 6.86	1,753,144	I	By Subsidiary (1)
Common Stock	01/03/2007		P		1,200	A	\$ 6.92	1,754,344	I	By Subsidiary (1)
Common Stock	02/01/2007		P		800	A	\$ 7.8	1,755,144	I	By Subsidiary

Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

									(1)
Common Stock	02/01/2007	S	500	D	\$ 7.85	1,754,644	I		By Subsidiary (1)
Common Stock	02/05/2007	P	18,400	A	\$ 7.84	1,773,044	I		By Subsidiary (1)
Common Stock	02/13/2007	P	675,000	A	\$ 8.44	2,448,044	I		By Subsidiary (1)
Common Stock	03/01/2007	P	2,600	A	\$ 7.82	2,450,644	I		By Subsidiary (1)
Common Stock	03/02/2007	P	12,700	A	\$ 7.88	2,463,344	I		By Subsidiary (1)
Common Stock	03/05/2007	P	700	A	\$ 7.6	2,464,044	I		By Subsidiary (1)
Common Stock	03/05/2007	P	5,000	A	\$ 7.73	2,469,044	I		By Subsidiary (1)
Common Stock	03/06/2007	P	1,600	A	\$ 7.52	2,470,644	I		By Subsidiary (1)
Common Stock	04/02/2007	S	17,100	D	\$ 7.75	2,453,544	I		By Subsidiary (1)
Common Stock	04/02/2007	P	17,100	A	\$ 7.75	2,470,644	I		By Subsidiary (1)
Common Stock	04/02/2007	P	4,639	A	\$ 7.67	2,475,283	I		By Subsidiary (1)
Common Stock	04/02/2007	P	23,000	A	\$ 7.72	2,498,283	I		By Subsidiary (1)
Common Stock	04/03/2007	P	16,561	A	\$ 7.8	2,514,844	I		By Subsidiary (1)
Common Stock	05/01/2007	P	12,500	A	\$ 7.77	2,527,344	I		By Subsidiary (1)

Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

Common Stock	05/02/2007		P	6,800	A	\$ 7.7	2,534,144	I	By Subsidiary (1)
Common Stock	06/04/2007		S	100	D	\$ 12	2,534,044	I	By Subsidiary (1)
Common Stock	06/13/2007		P	120,900	A	\$ 7.89	2,654,944	I	By Subsidiary (1)
Common Stock	07/02/2007		P	45,900	D	\$ 6.5	2,700,844	I	By Subsidiary (1)
Common Stock	07/02/2007		S	45,900	D	\$ 6.5	2,654,944	I	By Subsidiary (1)
Common Stock	08/01/2007		S	1,400	D	\$ 5.17	2,653,544	I	By Subsidiary (1)
Common Stock	08/01/2007		S	1,400	A	\$ 5.15	2,652,144	I	By Subsidiary (1)
Common Stock	08/01/2007		P	350,000	A	\$ 4.8	3,002,144	I	By Subsidiary (1)
Common Stock	10/16/2007		P	23,380	A	\$ 5.47	3,025,524	I	By Subsidiary (1)
Common Stock	10/16/2007		P	50,000	A	\$ 5.5	3,075,524	I	By Subsidiary (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
--	--	--------------------------------------	--	--------------------------------	---	--	---

